Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07147192 · ClinicalTrials.gov registry record · NA

Feasibility Study of an Accommodating IOL Design

A NA study of Aphakia, sponsored by Alcon Research.

Recruiting
Registry status
NA
Development phase
85
Enrollment target
5
Study locations

NCT07147192: Recruiting NA study of Aphakia, sponsored by Alcon Research.

NCT07147192 is a NA study of Aphakia that is actively recruiting participants, run by Alcon Research. The registered enrollment target is 85 participants, below the 198-participant average among 5 other Aphakia trials with a reported enrollment target (57% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07147192, a NA study of Aphakia, is actively recruiting participants, sponsored by Alcon Research.

RECRUITING
Registry status
NA
Development phase
85 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this clinical study is to assess safety and explore usability and effectiveness of the test product, AAL-FAIOL. This study will be conducted in Central America.

Conditions Studied

Interventions

  • PROCEDURE Phacoemulsification
  • DEVICE AAL-FAIOL
  • DEVICE BAL-FAIOL

Study Locations (5)

Other

  • Clinica 20/20 - San José
  • Instituto Espaillat Cabral - Santo Domingo
  • Centro Panamericano de Ojos / Clinica Lopez Beltran - San Salvador
  • Panama Eye Center - Panama City

Texas

  • Contact Alcon Call Center for Trial Locations - Fort Worth

Trial Details

FieldValue
Enrollment Target 85 participants
Start Date 2025-12-03
Est. Completion 2027-11
Phase NA
Alcon Research

275 total trials

What NCT07147192 shows while recruiting

NCT07147192 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 198-participant average among 5 other Aphakia trials with a reported enrollment target (57% lower).

The record links to 1 condition, with Aphakia appearing as the primary indexed condition, and to 3 interventions - of which Phacoemulsification is the first listed.

NCT07147192 lists 5 locations in 2 states (Other, Texas).

Frequently Asked Questions

What is clinical trial NCT07147192 about?

NCT07147192 is a clinical study titled "Feasibility Study of an Accommodating IOL Design". The purpose of this clinical study is to assess safety and explore usability and effectiveness of the test product, AAL-FAIOL. This study will be conducted in Central America.

What is the current status of trial NCT07147192?

This trial is currently recruiting. It is a NA study. The enrollment target is 85 participants. The study started on 2025-12-03. Estimated completion is 2027-11.

What conditions does trial NCT07147192 study?

This clinical trial studies the following conditions: Aphakia.

What interventions are being tested in trial NCT07147192?

The interventions under investigation include: Phacoemulsification (PROCEDURE), AAL-FAIOL (DEVICE), BAL-FAIOL (DEVICE).

Who is sponsoring clinical trial NCT07147192?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07147192 being conducted?

This trial has 5 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aphakia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00842283 · 85 participants

    Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target

  • NCT02133196 · 85 participants · Phase 2

    T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

  • NCT03823144 · 85 participants · NA

    Intravital Microscopy in Human Solid Tumors

  • NCT03875638 · 85 participants · Phase 2

    Treating Hyperexcitability in AD With Levetiracetam

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07147192, the US trial registry maintained by the National Library of Medicine. NCT07147192 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.